Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Status:
Terminated
Trial end date:
2016-08-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess objective response rate (ORR) in patients
with relapsed or refractory MCL who failed ibrutinib treatment or were unable to tolerate
ibrutinib.